Lipoxen presents positive results from Phase I diabetes study
Lipoxen, a biopharmaceutical company, has announced positive results from its completed Phase I trial of SuliXen, its long-acting insulin candidate for type 1 and type 2 diabetes. The
China-based clinical-stage biotechnology company BoomRay Pharmaceuticals and Novartis Pharma have signed an exclusive worldwide licence deal for an undisclosed preclinical radioligand therapy (RLT) asset in a deal worth up to $900m.
Subsequent to the recommendation for regulatory approval under the European decentralized procedure, Basilea received the marketing authorization for Toctino in Belgium and Luxemburg. Following the regulatory approval of